Small-molecule BACE1 inhibitors: A patent literature review (2006 - 2011)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 5, 2012, Pages 511-540

  Probst, Gary ^a   Xu, Ying Zi ^a  

^a ELAN PHARMACEUTICALS   (United States)

Author keywords

Alzheimer's disease; Amyloid hypothesis; BACE1; Small molecule BACE1 inhibitor

Indexed keywords

AMIDINE; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE INHIBITOR; AZ 3839; BETA SECRETASE 1; ETHANOLAMINE DERIVATIVE; HYDANTOIN; HYDANTOIN DERIVATIVE; HYDROXYL GROUP; MACROCYCLIC COMPOUND; MK 8931; SMALL MOLECULE BETA SECRETASE 1 INHIBITOR; STATINE; TERTIARY AMINE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ALZHEIMER DISEASE; DOWN SYNDROME; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; GENE MUTATION; GENETIC SUSCEPTIBILITY; IC 50; INCLUSION BODY MYOSITIS; MULTIPLE SCLEROSIS; PATENT; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; STEREOCHEMISTRY; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861512510     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.681302     Document Type: Review

References (364)

1. Alzheimer's Association. 2011 Alzheimer's Association Report Alzheimer's disease facts and figures. Alzheimers Dement 2011;7:208-44
2. Querfurth HW, LaFerla FM. Alzheimer's Disease. N Engl J Med 2010;362:329-44
3. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403
4. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011;377:1019-31
5. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
6. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-8
7. Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001;24:1121-59
8. Hardy JA, Higgins GA. Alzheimer's Disease: the Amyloid cascade hypothesis. Science 1992;256:184-5
9. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-98
10. Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 1999;96:11049-53
11. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010;6:99-107
12. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-98
13. Lleo A, Saura CA. gamma-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease. Curr Top Med Chem 2011;11:1513-27
14. Lleo A. Activity of gamma-secretase on substrates other than APP. Curr Top Med Chem 2008;8:9-16
15. Wong GT, Manfras D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-Amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82
16. Milano J, McKay J, Dagenais C, et al. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004;82:341-58
17. Roberds SL, Anderson J, Basi G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001;10:1317-24
18. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 2001;4:231-2
19. Luo Y, Bolon B, Damore MA, et al. BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003;14:81-8
20. McConlogue L, Buttini M, Anderson JP, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic Mice. J Biol Chem 2007;282:26326-34
21. Ohno M, Sametsky EA, Younkin LH, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's Disease. Neuron 2004;41:27-33
22. Hunt CE, Turner AJ. Cell biology, regulation and inhibition of beta-secretase (BACE-1). FEBS J 2009;276:1845-59
23. Vassar R, Kovacs DM, Yan R, Wong PC. The beta-secretase enzyme BACE in health and alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 2009;29:12787-94
24. Savonenko AV, Melnikova T, Laird FM, et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes inBACE1-null mice. Proc Natl Acad Sci USA 2008;105:5585-90
25. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, et al. Neuregulin 1 and schizophrenia. Ann Med 2004;36:62-71
26. Hu X, He W, Diaconu C, et al. Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves. FASEB J 2008;22:2970-80
27. Hu X, Hicks CW, He W, et al. BACE1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006;9:1520-5
28. Willem M, Garratt AN, Novak B, et al. Control of peripheral nerve myelination by the beta-Secretase BACE1. Science 2006;314:664-6
29. Hu X, Zhou X, He W, et al. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci 2010;30:8819-29
30. Laird FM, Cai H, Savonenko AV, et al. BACE1, a Major determinant of selective vulnerability of the brain to Amyloid-beta Amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 2005;25:11693-709
31. Sankaranarayanan S, Price EA, Wu G, et al. In Vivo beta-Secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on Neuregulin-1. J Pharmacol Exp Ther 2008;324:957-69
32. Lin X, Koelsch G, Wu S, et al. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci USA 2000;97:1456-60
33. Vassar R, Bennett BD, Babu-Khan S, et al. beta-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286:735-41
34. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402:537-40
35. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999;402:533-7
36. Hussain I, Powell D, Howlett DR, et al. Identification of a Novel Aspartic Protease (Asp 2) as beta-Secretase. Mol Cell Neurosci 1999;14:419-27
37. Turner RT, Loy JA, Nguyen C, et al. Specificity of memapsin 1 and its implications on the design of memapsin 2 (beta-Secretase) inhibitor selectivity. Biochemistry 2002;41:8742-6
38. Yang LB, Lindholm K, Yan R, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003;9:3-4
39. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. beta-Secretase protein and activity are increased in the neocortex in alzheimer disease. Arch Neurol 2002;59:1381-9
40. Fukumoto H, Rosene DL, Moss MB, et al. beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004;164:719-25
41. Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-Secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's Disease pathogenesis. J Neurosci 2005;25:10874-83
42. Li R, Lindholm K, Yang LB, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 2004;101:3632-7
43. O'Connor T, Sadleir KR, Maus E, et al. Phosphorylation of the translation initiation factor eIF2a increases BACE1 levels and promotes amyloidogenesis. Neuron 2008;60:988-1009
44. Nikolaev A, McLaughlin T, O'Leary DDM, Teesier-Lavign M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457:981-90
45. Gotz J, Eckert A, Matamales M, et al. Modes of Abeta toxicity in Alzheimer's disease. Cell Mol Life Sci 2011;68:3359-75
46. Stern EA, Bacskai BJ, Hickey GA, et al. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci 2004;24:4535-40
47. Tsai J, Grutzendler J, Duff K, Gan WB. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004;7:1181-3
48. Cummings BJ, Pike CJ, Shankle R, Cotman CW. beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996;17:921-33
49. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007;8:101-12
50. Catalano SM, Dodson EC, Henze DA, et al. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 2006;6:597-608
51. Gong Y, Chang L, Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric Abeta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003;100:10417-22
52. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-53
53. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-7
54. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84
55. Cheng IH, Scearce-Levie K, Legleiter J, et al. Accelerating Amyloid-beta fibrillization reduces oligomer levels and functional deficits in mouse models of Alzheimer disease. J Biol Chem 2007;282:23818-28
56. Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of Abeta1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000;20:4050-8
57. Holcomb LA, Gordon MN, Jantzen P, et al. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet 1999;29:177-85
58. Hsia A, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999;96:3228-33
59. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J Am Med Assoc 2000;283:1571-7
60. McLean CA, Cherny RA, Fraser FW, et al. Soluble Pool of Abeta Amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999;46:860-6
61. Lue LF, Kuo YM, Roher AE, et al. Soluble Amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999;155:853-62
62. Wang J, Dickson DW, Trojanowski JQ, Lee VMY. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 1999;158:328-37
63. Arispe N, Rojas E, Pollard HB. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 1993;90:567-71
64. Demuro A, Mina E, Kayed R, et al. Calcium Dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005;280:17294-300
65. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008;31:454-63
66. Green KM, LaFerla FM. Linking calcium to Abeta and Alzheimer's disease. Neuron 2008;59:190-4
67. De Felice FG, Wu D, Lambert MP, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging 2008;29:1334-47
68. Ryan SD, Whitehead SN, Swayne LA, et al. Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism. Proc Natl Acad Sci USA 2009;106:20936-41
69. Jin M, Shepardson N, Yang T, et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 2011;108:5819-24
70. Rapoport M, Dawson HN, Binder LI, et al. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002;99:6364-9
71. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42
72. Gotz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301L Tau transgenic mice induced by Abeta42 fibrils. Science 2001;293:1491-5
73. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
74. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
75. Li S, Hong S, Shepardson NE, et al. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009;62:788-801
76. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9
77. Townsend M, Qu Y, Gray A, et al. Oral treatment with a gamma-Secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2010;333:110-19
78. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8:499-509
79. Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004;304:448-52
80. Manczak M, Anekonda TS, Henson E, et al. Mitochondria are a direct site of Abeta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006;15:1437-49
81. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66
82. Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Ann Rev Genet 1998;32:461-93
83. Hutton M, Hardy J. The presenilins and Alzheimer's disease. Hum Mol Genet 1997;6:1639-46
84. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997;20:154-9
85. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303
86. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009;10:333-44
87. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzherimer's disease. Proc Natl Acad Sci USA 2002;99:5644-51
88. Miners JS, Barua N, Kehoe PG, et al. Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011;70:944-59
89. Miners JS, Baig S, Palmer J, et al. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008;18:240-52
90. Iwata N, Tsubuki S, Akaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-50
91. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-7
92. Tokuda T, Calero M, Matsubara E, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J 2000;348:359-65
93. Caccamo A, Oddo S, Sugarman MC, et al. Age- and region dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 2005;26:645-54
94. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008;58:681-93
95. Saito T, Iwata N, Tsubuki S, et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 2005;11:434-9
96. Grouselle D, Winsky-Sommerer R, David JP, et al. Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett 1998;255:21-4
97. Miners JS, Van Helmond Z, Chalmers K, et al. Decreased expression and activity of neprilysin in alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 2006;65:1012-21
98. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-e4 Allele. Am J Pathol 2003;162:313-19
99. Jiang Y, Mullaney KA, Peterhoff CM, et al. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA 2010;107:1630-5
100. Greenberg SA. Inclusion body myositis. Curr Opin Rheumatol 2011;23:574-8
101. Zipfel GJ, Han H, Ford AL, Lee JM. Unit cerebral amyloid angiopathy: progressive disruption of the neurovascular. Stroke 2009;40:S16-19
102. Woodard-Grice AV, McBrayer AC, Wakefield JK, et al. Proteolytic Shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins. J Biol Chem 2008;283:26364-73
103. Boehringer Ingelheim. WO06050861; 2006
104. Comentis, Inc. US7335632; 2008
105. Koike M, Nakanishi H, Saftig P, et al. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci 2000;20:6898-906
106. Ness D, Buttini M, Jordan W, et al. Neuropathology associated with administration of a nonselective Beta Secretase (BACE) and Cathepsin D inhibitor in Mdr 1a/b knockout mice. International Conference of Alzheimer's Disease; 16 - 21 July 2011; Paris, France
107. Medivir AB. WO08119773; 2008
108. Medivir AB. WO08119772; 2008
109. Medivir AB. WO08135488; 2008
110. Elan Pharmaceuticals, Inc. WO07047306; 2007
111. Elan Pharmaceuticals, Inc. WO07047305; 2007
112. Elan Pharmaceuticals, Inc. WO06010095; 2006
113. Elan Pharmaceuticals, Inc. WO06010094; 2006
114. Elan Pharmaceuticals, Inc. US7385085; 2008
115. Truong AP, Toth G, Probst GD, et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett 2010;20:6231-6
116. Sealy JM, Truong AP, Tso L, et al. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents. Bioorg Med Chem Lett 2009;19:6386-91
117. Truong AP, Probst GD, Aquino J, et al. Improving the permeability of the hydroxyethylamine BACE-1 inhibitors: structure-activity relationship of P2' substituents. Bioorg Med Chem Lett 2010;20:4789-94
118. Probst GD, Bowers S, Sealy JM, et al. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Bioorg Med Chem Lett 2010;20:6034-9
119. Pfizer, Inc. WO07110727; 2007
120. Pfizer, Inc. WO07060526; 2007
121. Pfizer, Inc. WO06064324; 2006
122. Pfizer, Inc. WO06085216; 2006
123. Amgen, Inc. WO08147547; 2008
124. Amgen, Inc. WO09064418; 2009
125. Amgen, Inc. WO08147544; 2008
126. Amgen, Inc. WO07062007; 2007
127. Amgen, Inc. WO07061930; 2007
128. Amgen, Inc. WO07061670; 2007
129. Amgen, Inc. US7872009; 2009
130. Amgen Inc. US7803809; 2010
131. Amgen, Inc. US7745484; 2010
132. Amgen Inc. US7838676; 2010
133. Kuhn B, Mohr P, Stahl M. Intramolecular hydrogen bonding in medicinal chemistry. J Med Chem 2010;53:2601-11
134. Novartis AG. WO08062044; 2008
135. Pfizer, Inc. WO06032999; 2006
136. Pfizer, Inc. WO06033000; 2006
137. Glaxo Group Ltd. WO06103088; 2006
138. Glaxo Group Ltd. WO06040151; 2006
139. Clarke B, Cutler L, Demont E, et al. BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296. Bioorg Med Chem Lett 2010;20:4639-44
140. Charrier N, Clarke B, Cutler L, et al. Second generation of BACE-1 inhibitors part 3: towards non hydroxyethylamine transition state mimetics. Bioorg Med Chem Lett 2009;19:3674-8
141. Charrier N, Clarke B, Demont E, et al. Second generation of BACE-1 inhibitors part 2: optimisation of the non-prime side substituent. Bioorg Med Chem Lett 2009;19:3669-73
142. Charrier N, Clarke B, Cutler L, et al. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. Bioorg Med Chem Lett 2009;19:3664-8
143. Charrier N, Clarke B, Cutler L, et al. Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability. J Med Chem 2008;51:3313-17
144. Beswick P, Charrier N, Clarke B, et al. BACE-1 inhibitors part 3: Identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorg Med Chem Lett 2008;18:1022-6
145. Clarke B, Demont E, Dingwall C, et al. BACE -1 inhibitors part 2: Identification of hydroxy ethylamines (HEAs) with reduced peptidic character. Bioorg Med Chem Lett 2008;18:1017-21
146. Clarke B, Demont E, Dingwall C, et al. BACE-1 inhibitors Part 1: Identification of novel hydroxyethylamines (HEAs). Bioorg Med Chem Lett 2008;18:1011-16
147. Glaxo Group Ltd. WO06040148; 2006
148. Glaxo Group Ltd. WO06040149; 2006
149. Comentis, Inc. and Purdue Research Foundation. WO09042694; 2009
150. Comentis, Inc. and Purdue Research Foundation. WO06110668; 2006
151. Comentis, Inc. and Purdue Research Foundation. WO09015369; 2009
152. Medivir AB. WO10107384; 2010
153. Medivir AB. WO10042030; 2010
154. LG Life Sciences Ltd. WO09038411; 2009
155. LG Life Sciences Ltd. WO09038412; 2009
156. Novartis AG. WO09013293; 2009
157. Eli Lilly and Co. WO06034093; 2006
158. Schering Corp. WO06014762; 2006
159. Schering Corp. US07662816; 2010
160. Schering Corp. US07598250; 2009
161. Iserloh U, Pan J, Stamford AW, et al. Discovery of an orally efficacious 4-phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg Med Chem Lett 2008;18:418-22
162. Iserloh U, Wu Y, Cumming JN, et al. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors. Bioorg Med Chem Lett 2008;18:414-17
163. Cumming JN, Le TX, Babu S, et al. Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. Bioorg Med Chem Lett 2008;18:3236-41
164. Merck & Co., Inc. WO07058862; 2007
165. Barrow JC, Rittle KE, Ngo PL, et al. Design and synthesis of 2,3,5-substituted imidazolidin-4-one inhibitors of BACE-1. ChemMedChem 2007;2:995-9
166. Bristol-Myers Squibb Co. WO06099352; 2006
167. Thompson LA, Shi J, Decicco CP, et al. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors. Bioorg Med Chem Lett 2011;21:6909-15
168. Boy KM, Guernon JM, Shi J, et al. Monosubstituted gamma-lactam and conformationally constrained 1,3- diaminopropan-2-ol transition-state isostere inhibitors of beta-secretase (BACE). Bioorg Med Chem Lett 2011;21:6916-24
169. Comentis, Inc. and Purdue Research Foundation and Astellas Pharma. WO10110817; 2010
170. Comentis, Inc. WO11044057; 2011
171. Comentis, Inc. WO11130383; 2011
172. Comentis, Inc. and Purdue Research Foundation and Astellas Pharma. WO10042892; 2010
173. Purdue Research Foundation. WO10042796; 2010
174. Novartis AG. WO10003976; 2010
175. Novartis AG. WO09024615; 2009
176. Novartis AG. WO07093621; 2007
177. Rueeger H, Rondeau JM, McCarthy C, et al. Structure based design, synthesis and SAR of cyclic hydroxyethylamine (HEA) BACE-1 inhibitors. Bioorg Med Chem Lett 2011;21:1942-7
178. Novartis AG. WO08009734; 2008
179. Machauer R, Laumen K, Veenstra S, et al. Macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors with activity in vivo. Bioorg Med Chem Lett 2009;19:1366-70
180. Machauer R, Veenstra S, Rondeau JR, et al. Structure-based design and synthesis of macrocyclic peptidomimetic beta-secretase (BACE-1) inhibitors. Bioorg Med Chem Lett 2009;19:1361-5
181. Novartis AG. WO07077004; 2007
182. Novartis AG. WO06074950; 2006
183. Lerchner A, Machauer R, Betschart C, et al. Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. Bioorg Med Chem Lett 2010;20:603-7
184. Novartis AG. WO06074940; 2006
185. Novartis AG. WO08009750; 2008
186. Schering Corp. WO06014944; 2006
187. Merck & Co., Inc. WO06057945; 2006
188. Rajapakse HA, Nantermet PG, Selnick HG, et al. Discovery of oxadiazoyl tertiary carbinamine inhibitors of beta-secretase (BACE-1). J Med Chem 2006;49:7270-3
189. Zhu H, Young MB, Nantermet PG, et al. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors. Bioorg Med Chem Lett 2010;20:1779-82
190. Stanton MG, Stauffer SR, Gregro AR, et al. Discovery of isonicotinamide derived beta-Secretase Inhibitors: in vivo reduction of beta-Amyloid. J Med Chem 2007;50:3431-3
191. Stauffer SR, Stanton MG, Gregro AR, et al. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a N-terminal 10sloop down conformation. Bioorg Med Chem Lett 2007;17:1788-92
192. McGaughey GB, Colussi D, Graham SL, et al. beta-Secretase (BACE-1) inhibitors: Accounting for 10s loop flexibility using rigid active sites. Bioorg Med Chem Lett 2007;17:1117-21
193. Rajapakse HA, Nantermet PG, Selnick HG, et al. SAR of tertiary carbinamine derived BACE1 inhibitors: Role of aspartate ligand amine pKa in enzyme inhibition. Bioorg Med Chem Lett 2010;20:1885-9
194. Sankaranarayanan S, Holahan MA, Colussi D, et al. First demonstration of cerebrospinal fluid and plasma Abeta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 2009;328:131-40
195. Nantermet PG, Rajapakse HA, Stanton MG, et al. Evolution of tertiary carbinamine BACE-1 inhibitors: Abeta reduction in rhesus CSF upon oral dosing. ChemMedChem 2009;4:37-40
196. Merck & Co., Inc. WO06078577; 2006
197. Merck & Co., Inc. WO06078576; 2006
198. Merck & Co., Inc. WO07019080; 2007
199. Merck & Co., Inc. WO07019078; 2007
200. Merck & Co., Inc. WO07019111; 2007
201. Merck & Co., Inc. WO06055434; 2006
202. Lindsley SR, Moore KP, Rajapakse HA, et al. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007;17:4057-61
203. Moore KP, Zhu H, Rajapakse HA, et al. Strategies toward improving the brain penetration of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg Med Chem Lett 2007;17:5831-5
204. Stachel SJ, Coburn CA, Sankaranarayanan S, et al. Macrocyclic inhibitors of beta-secretase: functional activity in an animal model. J Med Chem 2006;49:6147-50
205. Merck & Co., Inc. WO06057983; 2006
206. Merck & Co., Inc. WO08036316; 2008
207. Merck & Co., Inc. WO06002004; 2006
208. Merck & Co., Inc. WO09078932; 2009
209. Merck & Co., Inc. WO10094242; 2010
210. Stachel SJ, Steele TG, Petrocchi A, et al. Discovery of pyrrolidine-based betasecretase inhibitors: Lead advancementthrough conformational design for maintenance of ligand binding efficiency. Bioorg Med Chem Lett 2012;22:240-4
211. Boehringer Ingelheim. WO07014946; 2007
212. Boehringer Ingelheim. WO07017510; 2007
213. Boehringer Ingelheim. WO07017509; 2007
214. Boehringer Ingelheim. WO07017507; 2007
215. Boehringer Ingelheim. WO06103038; 2006
216. Purdue Research Foundation. WO10065861; 2010
217. Merck & Co., Inc. WO06044497; 2006
218. Merck & Co., Inc. WO07011810; 2007
219. Merck & Co., Inc. WO07011833; 2007
220. Barrow JC, Stauffer SR, Rittle KE, et al. Discovery and X-ray Crystallographic Analysis of a Spiropiperidine Iminohydantoin Inhibitor of beta-Secretase. J Med Chem 2008;51:6259-62
221. Merck & Co., Inc. WO08085509; 2008
222. Merck & Co., Inc. WO08045250; 2008
223. Pfizer, Inc. WO09136350; 2009
224. Brodney M. Beta-secretase inhibitors for treatment of Alzheimer's disease. 239th ACS National Meeting & Exposition; 21 - 25 March 2010; San Francisco, CA
225. Pfizer, Inc. WO11125006; 2011
226. Pfizer, Inc. WO10058333; 2010
227. Amgen, Inc. WO11063233; 2011
228. Amgen, Inc. WO11063272; 2011
229. Amgen, Inc. WO11090911; 2011
230. Cheng Y, Judd TC, Bartberger MD, et al. From Fragment Screening to In Vivo Efficacy: Optimization of a Series of 2-Aminoquinolines as Potent Inhibitors of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1). J Med Chem 2011;54:5836-57
231. Janssen Pharmaceutica N. V. WO09097401; 2009
232. Janssen Pharmaceutica N. V. WO09097278; 2009
233. Janssen Pharmaceutica N. V. WO07092854; 2007
234. Janssen Pharmaceutica N. V. WO07092846; 2007
235. Janssen Pharmaceutica N. V. WO07050612; 2007
236. Janssen Pharmaceutica N. V. WO06024932; 2006
237. Janssen Pharmaceutica N. V. WO06017844; 2006
238. Janssen Pharmaceutica N. V. WO06017836; 2006
239. Janssen Pharmaceutica N. V. WO07092839; 2007
240. Baxter EW, Conway KA, Kennis L, et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem 2007;50:4261-4
241. Huang Y, Strobel ED, Ho CY, et al. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. Bioorg Med Chem Lett 2010;20:3158-60
242. Purdue Research Foundation. WO10059953; 2010
243. Boehringer Ingelheim. WO09007300; 2009
244. Boehringer Ingelheim. WO09092566; 2009
245. Merck & Co., Inc. WO09108550; 2009
246. Hills ID, Holloway MK, de Leon P, et al. A conformational constraint improves a beta-secretase inhibitor but for an unexpected reason. Bioorg Med Chem Lett 2009.19:4993-5
247. Stachel SJ, Coburn CA, Rush D, et al. Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1. Bioorg Med Chem Lett 2009;19:2977-80
248. Merck & Co., Inc. WO06060109; 2006
249. Shionogi & Co., Ltd. WO10047372; 2 1
250. Wyeth. US7732457; 2010
251. Wyeth. WO08036196; 2008
252. Malamas MS, Barnes K, Hui Y, et al. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010;20:2068-73
253. Wyeth. US7488832; 2009
254. Wyeth. US7285682; 2007
255. Cole DC, Stock JR, Chopra R, et al. Acylguanidine inhibitors of beta-secretase: Optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 2008;18:1063-6
256. Jennings LD, Cole DC, Stock JR, et al. Acylguanidine inhibitors of beta-secretase: Optimization of the pyrrole ring substituents extending into the S'1 substrate binding pocket. Bioorg Med Chem Lett 2008;18:767-71
257. Cole DC, Manas ES, Stock JR, et al. Acylguanidines as small-molecule betasecretase inhibitors. J Med Chem 2006;49:6158-61
258. Fobare WF, Solvibile WR, Robichaud AJ, et al. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett 2007;17:5353-6
259. Bristol-Myers Squibb Co. WO07002214; 2007
260. AstraZeneca AB and Astex Therapeutics Ltd. WO07120096; 2007
261. Shionogi & Co., Ltd. WO10113848; 2010
262. Wyeth. US7452885; 2008
263. Zhou P, Li Y, Fan Y, et al. Pyridinyl aminohydantoins as small molecule BACE1 inhibitors. Bioorg Med Chem Lett 2010;20:2326-9
264. Malamas MS, Barnes K, Johnson M, et al. Di-substituted pyridinyl aminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem 2010;18:630-9
265. Malamas MS, Erdei J, Gunawan I, et al. Design and Synthesis of 5,5'-Disubstituted Aminohydantoins as Potent and Selective Human beta-Secretase (BACE1) Inhibitors. J Med Chem 2010;53:1146-58
266. Wyeth. WO08118379; 2008
267. Wyeth. WO08115552; 2008
268. Wyeth. US7723368; 2010
269. Wyeth. US7700602; 2010
270. Wyeth. US7482349; 2009
271. Wyeth. US7423158; 2008
272. Malamas MS, Robichaud A, Erdei J, et al. Design and synthesis of aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett 2010;20:6597-605
273. Wyeth. US7705030; 2010
274. Wyeth. US7417047; 2008
275. Malamas MS, Erdei J, Gunawan I, et al. New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: Exploring the S2' region. Bioorg Med Chem Lett 2011;21:5164-70
276. AstraZeneca AB and Astex Therapeutics Ltd. WO08076045; 2008
277. AstraZeneca AB and Astex Therapeutics Ltd. WO08076044; 2008
278. AstraZeneca AB and Astex Therapeutics Ltd. WO08076043; 2008
279. AstraZeneca AB and Astex Therapeutics Ltd. WO07058601; 2007
280. AstraZeneca AB and Astex Therapeutics Ltd. WO08076046; 2008
281. AstraZeneca AB and Astex Therapeutics Ltd. WO07058602; 2007
282. Nowak P, Cole DC, Aulabaugh A, et al. Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010;20:632-5
283. Wyeth. WO07078813; 2007
284. Schering Corp. US7700603; 2010
285. Schering Corp. US7592348; 2009
286. Zhu Z, Sun ZY, Ye Y, et al. Discovery of Cyclic Acylguanidines as Highly Potent and Selective beta-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part I-Inhibitor Design and Validation. J Med Chem 2010;53:951-65
287. Cumming JN, Smith EM, Wang L, et al. Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett 2012;22:2444-9
288. Noscira S.A. WO11015646; 2011
289. F. Hoffman-La and Siena Biotech S.P.A. WO09103626; 2009
290. AstraZeneca AB. WO11002408; 2011
291. AstraZeneca AB. WO11002407; 2011
292. Wyeth. US7456186; 2008
293. Wyeth. WO08022024; 2008
294. Wyeth. WO06076284; 2006
295. Malamas MS, Erdei J, Gunawan I, et al. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem 2009;52:6314-23
296. AstraZeneca AB and Astex Therapeutics Ltd. WO07145570; 2007
297. AstraZeneca AB and Astex Therapeutics Ltd. WO07145568; 2007
298. AstraZeneca AB and Astex Therapeutics Ltd. WO08063114; 2008
299. AstraZeneca AB and Astex Therapeutics Ltd. WO07145571; 2007
300. AstraZeneca AB. WO11002409; 2011
301. AstraZeneca AB. WO10056196; 2010
302. AstraZeneca AB. WO10056195; 2010
303. AstraZeneca AB and Astex Therapeutics Ltd. WO10056194; 2010
304. AstraZeneca AB and Astex Therapeutics Ltd. WO09005471; 2009
305. AstraZeneca AB and Astex Therapeutics Ltd. WO09005470; 2009
306. AstraZeneca AB and Astex Therapeutics Ltd. WO07149033; 2007
307. AstraZeneca AB and Astex Therapeutics Ltd. US7629356; 2009
308. Swahn BM, Holenz J, Kihlstroem J, et al. Aminoimidazoles as BACE -1 inhibitors: The challenge to achieve in vivo brain efficacy. Bioorg Med Chem Lett 2012;22:1854-9
309. Vitae Pharmaceuticals, Inc. and Boehringer Ingelheim. WO11106414; 2011
310. Vitae Pharmaceuticals, Inc. and Boehringer Ingelheim. WO10105179; 2010
311. Vitae Pharmaceuticals, Inc. WO10021680; 2010
312. Amgen, Inc. WO10030954; 2010
313. Amgen, Inc. WO11115938; 2011
314. Array Biopharma, Inc. and Genentech, Inc. WO11130741; 2011
315. Array Biopharma, Inc. and Genentech, Inc. WO11123674; 2011
316. Array Biopharma, Inc. WO11072064; 2011
317. Wyeth. US7582667; 2009
318. AstraZeneca AB and Astex Therapeutics Ltd. WO07073284; 2007
319. AstraZeneca AB and Astex Therapeutics Ltd. WO06041405; 2006
320. AstraZeneca AB and Astex Therapeutics Ltd. WO06041404; 2006
321. AstraZeneca AB and Astex Therapeutics Ltd. WO07114771; 2007
322. Shionogi & Co., Ltd. WO10047372; 2010
323. Schering Corp. US7763609; 2010
324. Schering Corp. WO08103351; 2008
325. Scott JD, Li SW, Gilbert EJ, et al. Novel iminopyrimidinone beta-secretase (BACE) inhibitors: P1-thiophenes. 241st ACS National Meeting & Exposition; 27 - 31 March 2011; Anaheim, CA
326. Schering Corp. WO11044185; 2011
327. Eisai R&D Management Co., Ltd. WO11009897; 2011
328. Schering Corp. WO09131974; 2009
329. Schering Corp. WO09131975; 2009
330. Schering Corp. WO11044187; 2011
331. Eli Lilly and Co. WO09134617; 2009
332. May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 2011;31:16507-16
333. Shionogi & Co., Ltd. WO11058763; 2011
334. Shionogi & Co., Ltd. WO07049532; 2007
335. Eisai R&D Management Co., Ltd. WO10013302; 2010
336. Eisai R&D Management Co., Ltd. WO10013794; 2010
337. Shionogi & Co., Ltd. WO08133274; 2008
338. Shionogi & Co., Ltd. WO08133273; 2008
339. Eisai R&D Management Co., Ltd. WO09091016; 2009
340. Eisai R&D Management Co., Ltd. WO10038686; 2010
341. Eli Lilly and Co. WO11005738; 2011
342. Shionogi & Co., Ltd. WO11070781; 2011
343. Shionogi & Co., Ltd. WO11071057; 2011
344. F. Hoffman-La Roche and Siena Biotech S.P.A. WO11069934; 2011
345. Shionogi & Co., Ltd. WO11071135; 2011
346. Eisai R&D Management Co., Ltd. WO11009898; 2011
347. Shionogi & Co., Ltd. WO11071109; 2011
348. Shionogi & Co., Ltd. WO11077726; 2011
349. F. Hoffman-La Roche and Siena Biotech S.P.A. WO11020806; 2011
350. Novartis AG. WO11080176; 2011
351. Janssen Pharmaceutica N. V. WO11154431; 2011
352. Novartis AG. WO11009943; 2011
353. Janssen Pharmaceutica N. V. WO11154374; 2011
354. Tresadern G, Delgado F, Delgado O, et al. Rational design and synthesis of aminopiperazinones as beta-secretase (BACE) inhibitors. Bioorg Med Chem Lett 2011;21:7255-60
355. Amgen, Inc. WO11115928; 2011
356. AstraZeneca AB and Astex Therapeutics Ltd. WO07058583; 2007
357. F. Hoffman-La Roche and Siena Biotech S.P.A. WO11138293; 2011
358. High Point Pharmaceuticals, LLC. WO11119465; 2011
359. High Point Pharmaceuticals, LLC. WO10126745; 2010
360. High Point Pharmaceuticals, LLC. WO10126743; 2010
361. Transtech Pharma, Inc. WO06099379; 2006
362. Esbatech AG. WO06133588; 2006
363. Oncalis AG. WO07051333; 2007
364. Atwal JK, Chen Y, Chiu C, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 2011;3:1-12